Blog / Archives
Rayno Life Science Portfolio Biopharmaceuticals: ALXN, GILD, REGN, SGEN
Biotechnology Sector Continues Amazing Bull Run Up 40% YTD The Rayno Life Science Portfolio had nice gains today with 1% + moves from Biogen-Idec (BIIB) and Gilead Sciences (GILD) and with our...
Rayno Life Science Portfolio Dx and Tools: EXAS, ILMN,TMO
Molecular Plays Lead Rayno Dx Focus Stocks Up Illumina (ILMN) rose 4.5% today on "talk" that Roche will increase its buyout offer to $60. Roche told Bloomberg that it does not comment on rumors....
Who Knows About the Bull Market in Biotech Stocks?
Is There No End to the Biotech Bull Market? Biotech ETFs NASDAQ Biotechnology (IBB) up 36% YTD and NYSE (FBT) up 42% YTD Around 1998 I remember vividly two market conversations: one from a Sun Micro...
Rayno Life Science Portfolio: AMGN, EXAS, NEOG, REGN Winners on a Risk-Off Day
Biotech Stocks Remain Resilient On A Bad Day The market took a nasty turn today with a 1.36% sell-off in NASDAQ and 1.05% for the S&P. The damage was across the board but the healthcare sector...
NASDAQ Slips Down 0.4% But Biotech Sector Hits New Highs
The ETF IBB (142.62) hit an all time high today and is up 36.6% YTD. The low for IBB over two years was August 19, 2011 at $88.50. Our mid-cap biopharma index is up 0.8% with big winners in JAZZ...
Biotechnology Does Create Jobs and MASS Effort pays Off
The MASS Biotechnology industry has crossed $6B as a 25 year effort beginning in 1985 with the MASS Biotechnology Council. Several major biotechnology companies were created around this time such as...
Rayno Life Science Portfolio: ILMN, RGDX,QQQ
FED Policy Boosts Risk Assets -QQQs Should Outperform IBB We expect the biotech sector to slightly underperform NASDAQ (QQQ $70.22) in light of "QE Forever" yesterday and the shift to financials,...
“QE” Forever: Buy on Rumor, Buy on News- Market Up 1.5%
Gold, financials, energy and materials soar-Gold up $34 to $1767 You have been hearing about the FED and QE for weeks now and today announced a $40B/month purchase of mortgage securities and after...
You Know Its a Bull Market in Biotech When……Update 1 9/8/12
Valuations Don't Matter-Institutional Holders Are the Drivers Medivation (MDVN $105.65) sold off 3 pts Friday on modest volume today as profit taking ensued after the big run-up from the high 95....
Rayno Biopharmaceutical Portfolio: ASTX IMGN, PCYC
ImmunoGen Gets Boost on Breast Cancer Drug Survival Results Immunogen (IMGN $14.36) and Roche announced improved overall survival (OS) as well as progression free survival (PFS) in a Phase III trial...